Drugs.com - New Drug Approvals

U.S. FDA Approves Pfizer’s Braftovi Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE) December 20, 2024 -- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux® ) and mFOLFOX6...

Feb 9, 2025 - 22:25
 0
U.S. FDA Approves Pfizer’s Braftovi Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE) December 20, 2024 -- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux® ) and mFOLFOX6...
Read More

Tags:

Previous Article

FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the Treatment o...

Next Article

FDA Approves Zepbound (tirzepatide) as the First and Only Prescription Medicine ...

Related Posts

FDA Approves Expanded Use of Soliris (eculizumab) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children

FDA Approves Expanded Use of Soliris (eculizumab) for P...

Mar 31, 2025  0

FDA Approves Qfitlia (fitusiran) to Treat Hemophilia A or B With or Without Inhibitors

FDA Approves Qfitlia (fitusiran) to Treat Hemophilia A ...

Mar 30, 2025  0

Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Nemluvio (nemol...

Feb 9, 2025  0